SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-23-302252
Filing Date
2023-12-26
Accepted
2023-12-22 17:45:58
Documents
13
Period of Report
2023-11-08
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d613320d8ka.htm   iXBRL 8-K/A 25620
2 EX-99.3 d613320dex993.htm EX-99.3 208075
  Complete submission text file 0001193125-23-302252.txt   377810

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvmd-20231108.xsd EX-101.SCH 2887
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvmd-20231108_lab.xml EX-101.LAB 17943
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvmd-20231108_pre.xml EX-101.PRE 11271
7 EXTRACTED XBRL INSTANCE DOCUMENT d613320d8ka_htm.xml XML 4138
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

IRS No.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39219 | Film No.: 231510968
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)